Market capitalization | $1.78b |
Enterprise Value | $1.86b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 35.48 |
EV/Sales (TTM) EV/Sales | 4.98 |
P/S ratio (TTM) P/S ratio | 4.77 |
P/B ratio (TTM) P/B ratio | 1.69 |
Revenue growth (TTM) Revenue growth | 5.62% |
Revenue (TTM) Revenue | $372.80m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Certara forecast:
10 Analysts have issued a Certara forecast:
Sep '24 |
+/-
%
|
||
Revenue | 373 373 |
6%
6%
|
|
Gross Profit | 171 171 |
0%
0%
|
|
EBITDA | 66 66 |
23%
23%
|
EBIT (Operating Income) EBIT | 1.36 1.36 |
96%
96%
|
Net Profit | -31 -31 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.
Head office | United States |
CEO | William Feehery |
Employees | 1,391 |
Founded | 2008 |
Website | www.certara.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.